Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Non Operating Income (2016 - 2026)

Viking Therapeutics (VKTX) has disclosed Non Operating Income for 13 consecutive years, with $5.8 million as the latest value for Q1 2026.

  • For Q1 2026, Non Operating Income fell 41.06% year-over-year to $5.8 million; the TTM value through Mar 2026 reached $29.7 million, down 32.71%, while the annual FY2025 figure was $33.7 million, 17.71% down from the prior year.
  • Non Operating Income hit $5.8 million in Q1 2026 for Viking Therapeutics, down from $7.1 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $11.8 million in Q2 2024 and bottomed at $142000.0 in Q1 2022.
  • Average Non Operating Income over 5 years is $5.7 million, with a median of $5.8 million recorded in 2026.
  • Year-over-year, Non Operating Income soared 2168.84% in 2023 and then tumbled 41.06% in 2026.
  • Viking Therapeutics' Non Operating Income stood at $724000.0 in 2022, then soared by 546.41% to $4.7 million in 2023, then skyrocketed by 131.22% to $10.8 million in 2024, then crashed by 34.61% to $7.1 million in 2025, then decreased by 18.03% to $5.8 million in 2026.
  • According to Business Quant data, Non Operating Income over the past three periods came in at $5.8 million, $7.1 million, and $7.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.